Diabetes

A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, treatmentnaïve, uncontrolled Type 2 Diabetes Mellitus patients.

Register Today!

Let others know about this Trial!

Trial Information

StatusCompleted
Trial Duration24 weeks
Number of Visits10
Lead CRCJason Collin

For additional information
on this trial contact:

Phone705-566-0005